Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel F Hayes

Showing results (181-190 of 336) with videos related to

Pageof 34
Sort By:
Journal for Immunotherapy of Cancer|April 11, 2019
Immune profiling of pre- and post-treatment breast cancer tissues from the SWOG S0800 neoadjuvant trialXiaotong Li, Sarah Warren, Vasiliki Pelekanou, et al.
Breast Cancer Research and Treatment|March 14, 2020
Vitamin D deficiency increases severity of paclitaxel-induced peripheral neuropathyTheodore S Jennaro, Fang Fang, Kelley M Kidwell, et al.
Breast Cancer Research and Treatment|December 13, 2016
Effects of exemestane and letrozole therapy on plasma concentrations of estrogens in a randomized trial of postmenopausal women with breast cancerJason D Robarge, Zereunesay Desta, Anne T Nguyen, et al.
Psycho-Oncology|February 1, 2012
Randomized clinical trial of a brief and extensive dyadic intervention for advanced cancer patients and their family caregiversLaurel L Northouse, Darlene W Mood, Ann Schafenacker, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 7, 2016
Innovations in American Society of Clinical Oncology Practice Guideline DevelopmentMark R Somerfield, Kari Bohlke, George P Browman, et al.
Pharmacogenomics|December 7, 2018
Patients carrying CYP2C8*3 have shorter systemic paclitaxel exposureLauren A Marcath, Kelley M Kidwell, Adam C Robinson, et al.
Science Translational Medicine|August 2, 2013
Breaking a vicious cycleDaniel F Hayes, Jeff Allen, Carolyn Compton, et al.
The New England Journal of Medicine|August 20, 2004
Circulating tumor cells, disease progression, and survival in metastatic breast cancerMassimo Cristofanilli, G Thomas Budd, Matthew J Ellis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 22, 2009
Outcome of patients with early-stage breast cancer treated with doxorubicin-based adjuvant chemotherapy as a function of HER2 and TOP2A statusRaymond Tubbs, William E Barlow, G Thomas Budd, et al.
The American Journal of Pathology|February 13, 2010
Multiplexed assessment of the Southwest Oncology Group-directed Intergroup Breast Cancer Trial S9313 by AQUA shows that both high and low levels of HER2 are associated with poor outcomeMalini Harigopal, William E Barlow, Greg Tedeschi, et al.
Pageof 34

Showing results (181-190 of 336) with videos related to

Sort By:
Pageof 34
Journal for Immunotherapy of Cancer|April 11, 2019
Immune profiling of pre- and post-treatment breast cancer tissues from the SWOG S0800 neoadjuvant trialXiaotong Li, Sarah Warren, Vasiliki Pelekanou, et al.
Breast Cancer Research and Treatment|March 14, 2020
Vitamin D deficiency increases severity of paclitaxel-induced peripheral neuropathyTheodore S Jennaro, Fang Fang, Kelley M Kidwell, et al.
Breast Cancer Research and Treatment|December 13, 2016
Effects of exemestane and letrozole therapy on plasma concentrations of estrogens in a randomized trial of postmenopausal women with breast cancerJason D Robarge, Zereunesay Desta, Anne T Nguyen, et al.
Psycho-Oncology|February 1, 2012
Randomized clinical trial of a brief and extensive dyadic intervention for advanced cancer patients and their family caregiversLaurel L Northouse, Darlene W Mood, Ann Schafenacker, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 7, 2016
Innovations in American Society of Clinical Oncology Practice Guideline DevelopmentMark R Somerfield, Kari Bohlke, George P Browman, et al.
Pharmacogenomics|December 7, 2018
Patients carrying CYP2C8*3 have shorter systemic paclitaxel exposureLauren A Marcath, Kelley M Kidwell, Adam C Robinson, et al.
Science Translational Medicine|August 2, 2013
Breaking a vicious cycleDaniel F Hayes, Jeff Allen, Carolyn Compton, et al.
The New England Journal of Medicine|August 20, 2004
Circulating tumor cells, disease progression, and survival in metastatic breast cancerMassimo Cristofanilli, G Thomas Budd, Matthew J Ellis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 22, 2009
Outcome of patients with early-stage breast cancer treated with doxorubicin-based adjuvant chemotherapy as a function of HER2 and TOP2A statusRaymond Tubbs, William E Barlow, G Thomas Budd, et al.
The American Journal of Pathology|February 13, 2010
Multiplexed assessment of the Southwest Oncology Group-directed Intergroup Breast Cancer Trial S9313 by AQUA shows that both high and low levels of HER2 are associated with poor outcomeMalini Harigopal, William E Barlow, Greg Tedeschi, et al.
Pageof 34